Management of Advances Hepatocellular CarcinomaPratap Tiwari
Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide. For advanced HCC that cannot be treated with surgery or transplantation, the standard of care has been sorafenib. Lenvatinib and cabozantinib have also shown efficacy in advanced HCC. Immunotherapy with nivolumab has shown promise based on phase II data. Combination therapies and future targeted agents may provide additional treatment options for this difficult to treat cancer.
This document summarizes the management of hepatocellular carcinoma. It begins by introducing HCC as the most common form of liver cancer. It then discusses risk factors, surveillance methods, diagnosis via imaging and biopsy, and the BCLC staging system. The BCLC system links stage of disease to treatment options and expected survival outcomes. For early stages, curative treatments like resection, transplantation, and ablation are recommended. Intermediate stages receive transarterial chemoembolization, while advanced stages are treated with sorafenib. End-stage disease involves symptomatic support only.
1. Hepatocellular carcinoma (HCC) is the 6th most common cancer worldwide and has a high mortality rate of over 95%.
2. Chronic infection with hepatitis B and C viruses are the leading risk factors for HCC development, with cirrhosis being a prerequisite in many cases.
3. Screening high-risk individuals such as hepatitis B carriers and cirrhotic patients can detect HCC at an early stage and improve outcomes. Treatment options include surgical resection, liver transplantation, and local ablative therapies depending on tumor stage.
The guidelines provide an updated 2017 summary of clinical practice guidelines for the management of hepatocellular carcinoma (HCC) in the Asia-Pacific region. Key points include:
1) HCC is a major public health problem in the Asia-Pacific region, where the majority of HCC cases worldwide occur.
2) The guidelines provide evidence-based recommendations for treatment and management of HCC suitable for the diverse medical environments in the Asia-Pacific region.
3) Risk factors for HCC highlighted include chronic hepatitis B and C infections, cirrhosis of any etiology, alcohol abuse, and obesity. Incidence rates vary significantly within the region.
This document discusses the Barcelona Clinic Liver Cancer (BCLC) staging system for hepatocellular carcinoma. The BCLC staging system stratifies patients into 5 stages (0, A, B, C, D) based on tumor characteristics, liver function, physical status, and performance status. The stages determine first-line treatment options including surgical resection, liver transplantation, local ablation, transarterial chemoembolization, sorafenib, or palliative care. The BCLC staging system aims to predict outcomes and guide treatment selection. It is recommended by major liver organizations and has been validated in multiple studies.
HCC Clinical update and hints from AASLD 2017 guidelines mainly about surveillance, diagnosis and treatment of Hepatocellular carcinoma in different stages.
This lecture was part of an educational course performed by the IATTGI group this August in Buenos Aires and describes novel targets and novel drugs in hepatocellular carcinoma.
Management of Advances Hepatocellular CarcinomaPratap Tiwari
Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide. For advanced HCC that cannot be treated with surgery or transplantation, the standard of care has been sorafenib. Lenvatinib and cabozantinib have also shown efficacy in advanced HCC. Immunotherapy with nivolumab has shown promise based on phase II data. Combination therapies and future targeted agents may provide additional treatment options for this difficult to treat cancer.
This document summarizes the management of hepatocellular carcinoma. It begins by introducing HCC as the most common form of liver cancer. It then discusses risk factors, surveillance methods, diagnosis via imaging and biopsy, and the BCLC staging system. The BCLC system links stage of disease to treatment options and expected survival outcomes. For early stages, curative treatments like resection, transplantation, and ablation are recommended. Intermediate stages receive transarterial chemoembolization, while advanced stages are treated with sorafenib. End-stage disease involves symptomatic support only.
1. Hepatocellular carcinoma (HCC) is the 6th most common cancer worldwide and has a high mortality rate of over 95%.
2. Chronic infection with hepatitis B and C viruses are the leading risk factors for HCC development, with cirrhosis being a prerequisite in many cases.
3. Screening high-risk individuals such as hepatitis B carriers and cirrhotic patients can detect HCC at an early stage and improve outcomes. Treatment options include surgical resection, liver transplantation, and local ablative therapies depending on tumor stage.
The guidelines provide an updated 2017 summary of clinical practice guidelines for the management of hepatocellular carcinoma (HCC) in the Asia-Pacific region. Key points include:
1) HCC is a major public health problem in the Asia-Pacific region, where the majority of HCC cases worldwide occur.
2) The guidelines provide evidence-based recommendations for treatment and management of HCC suitable for the diverse medical environments in the Asia-Pacific region.
3) Risk factors for HCC highlighted include chronic hepatitis B and C infections, cirrhosis of any etiology, alcohol abuse, and obesity. Incidence rates vary significantly within the region.
This document discusses the Barcelona Clinic Liver Cancer (BCLC) staging system for hepatocellular carcinoma. The BCLC staging system stratifies patients into 5 stages (0, A, B, C, D) based on tumor characteristics, liver function, physical status, and performance status. The stages determine first-line treatment options including surgical resection, liver transplantation, local ablation, transarterial chemoembolization, sorafenib, or palliative care. The BCLC staging system aims to predict outcomes and guide treatment selection. It is recommended by major liver organizations and has been validated in multiple studies.
HCC Clinical update and hints from AASLD 2017 guidelines mainly about surveillance, diagnosis and treatment of Hepatocellular carcinoma in different stages.
This lecture was part of an educational course performed by the IATTGI group this August in Buenos Aires and describes novel targets and novel drugs in hepatocellular carcinoma.
The document summarizes hepatocellular carcinoma (HCC) and examines hepatitis C virus (HCV) as a risk factor. It provides descriptive epidemiology on HCC, identifying it as the 4th most common cancer worldwide. It then analyzes HCV as a major risk factor for HCC. Details are given on the virology, epidemiology, transmission routes, stages of infection, diagnosis and treatment of HCV, as well as its role in leading to HCC. Recommendations for primary prevention include national HBV vaccination programs and screening blood supplies.
Hepatocellular carcinoma—role of interventional radiologist Dr. Muhammad Bin ...Dr. Muhammad Bin Zulfiqar
Hepatocellular carcinoma is a leading cause of cancer death worldwide. Interventional radiologists play an important role in diagnosing and treating hepatocellular carcinoma. They can perform biopsies to determine disease, facilitate surgical treatment through techniques like portal vein embolization to increase eligibility for resection, and provide locoregional therapies for patients who are not surgical candidates like radiofrequency ablation, transarterial chemoembolization, and radioembolization. While offering palliation, these minimally invasive treatments can achieve local tumor control and prolong survival for some patients with hepatocellular carcinoma.
This document discusses hepatocellular carcinoma (HCC), the most common type of primary liver cancer. It notes that HCC typically develops in the setting of chronic liver disease. Worldwide, HCC is the 5th most common cancer and the 2nd leading cause of cancer death, with about 600,000 annual deaths. Risk factors for HCC include liver cirrhosis from various causes like viral hepatitis, as well as aflatoxin exposure. Screening with ultrasound and alpha-fetoprotein (AFP) testing every 6 months is recommended for high-risk patients to improve early detection and prognosis. Treatment options depend on tumor stage and liver function, and may include surgical resection, liver transplantation, ablation, and trans
Risk Stratification in Stage II Colon Cancer PatientsRamzi Amri
Objective: AJCC Stage II colon cancer patients form a group where the choice to either undergo or forego adjuvant chemotherapy is far from evident and often remains controversial. This study analyzes several pathological characteristics in order to assess their predictive value for outcomes in stage II colon cancer.
Design: Retrospective review of a prospectively maintained, IRB-approved data repository.
Setting: Tertiary care center.
Patients: A series of 313 consecutive stage II patients treated surgically for colon cancer at our center (2004-2011) were included.
Main outcome measures: Mortality, disease-specific mortality and metastasis, including multivariable Cox regression adjusted for stage subdivisions (II-A/II-B/II-C) and potential confounders.
Results: Colon cancer-specific mortality was substage-independently increased in patients with baseline carcinoembryonic antigen (CEA) >5ng/L (HR=2.97;P=0.041), large vessel invasion (HR=3.93; P=0.002) and perineural invasion (HR=3.67; P=0.004). Overall mortality adjusted for substage, age and comorbidity was also significantly higher in patients with high-grade disease (HR=2.73; P<0.001)><0.001).>5ng/L (HR=2.37; P=0.046), large vessel invasion (HR=2.80; P=0.002), perineural invasion (HR=2.57; P=0.010), and extramural vascular invasion (EMVI) (HR=2.83; P=0.002). The number of high-risk features (0,1,2-3,4+) was associated with a clearly incremental increase in disease-specific mortality (P=0.008) and recurrence (P<0.001).>5ng/L, large vessel invasion, perineural invasion and EMVI are all independent risk factors for recurrence and disease-specific mortality in Stage II colon cancer patients. The number of factors present form risk strata that should be weighed heavily in decisions regarding adjuvant treatment.
Liver cancer diagnostics and Future trendsThet Su Wynn
Liver cancer is usually diagnosed through a combination of tumor marker tests, imaging scans, and biopsy. Serum markers like AFP, AFP-L3, and PIVKA-II provide early screening but lack specificity. Ultrasound, CT, and MRI scans use contrast agents to detect hypervascular lesions during arterial wash-in and wash-out, but are not definitive. Biopsy confirms the diagnosis by examining tissue samples for liver cell abnormalities, fibrosis, and marker expression through histology and IHC staining. Future areas of research include improved non-invasive diagnostic tools using genetic markers like miRNA profiles and tumor-specific genes.
1) Liver transplantation provides the best chance of cure for hepatocellular carcinoma (HCC) in cirrhotic livers, but is limited by organ availability. The Milan criteria, which select patients with very early HCC, have been expanded to include slightly larger tumors without reducing survival.
2) Patients with HCC can be prioritized for liver transplant by receiving exception MELD scores, but these are only granted if tumors can be downstaged within defined criteria through treatments like ablation. Successful downstaging selects less aggressive tumors and predicts good post-transplant survival.
3) While downstaging expands access to transplant for some patients with larger tumors, eligibility criteria remain unclear as very advanced disease carries a
This document provides an overview of the management of hepatocellular carcinoma (HCC). It discusses the epidemiology, risk factors, diagnosis and staging, as well as treatment options for HCC. The major risk factors for HCC include hepatitis B virus, hepatitis C virus, and alcohol. Treatment depends on the stage and includes options such as liver transplantation, resection, ablation, transarterial chemoembolization, and the systemic therapy sorafenib. Prevention through vaccination and treating underlying liver diseases can help reduce cases of HCC.
This document provides the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Neuroendocrine and Adrenal Tumors. It was last updated in January 2019 and is authored by an expert panel assembled by NCCN. The guidelines provide evidence-based recommendations for diagnosis, staging, treatment and surveillance of neuroendocrine tumors and adrenal tumors. The key updates from the previous version include expanding the name to include adrenal tumors, preferring gallium-68 dotatate PET/CT for somatostatin receptor imaging, and adding peptide receptor radionuclide therapy with lutetium-177 as a treatment option.
Venous Thromboembolism in the Cancer Patientlarriva
Cancer patients are at an increased risk of venous thromboembolism. There have been several guidelines published on the topic from the American College of Chest Physicians (ACCP), the American Society of Clinical Oncology (ASCO), and the National Comprehensive Cancer Network (NCCN). Although they agree on some issues regarding prophylaxis and treatment there are several areas that vary. This presentation covers the varying recommendations and the areas of consensus (yellow boxes) among the guidelines while using a patient case to guide their interpretation.
Venous thromboembolism (VTE) can be the first sign of an underlying occult or undiagnosed cancer. The risk of occult cancer is higher in patients with unprovoked VTE compared to those with VTE from a provoking factor. Limited screening is recommended for patients over age 40 presenting with unprovoked VTE, including a complete blood count, basic metabolic panel, chest imaging, and consideration of tumor markers based on risk factors. More extensive screening with CT scans is not supported by evidence of improved outcomes and poses risks of unnecessary anticoagulation withdrawal or additional testing. Ongoing surveillance beyond initial screening may be warranted in certain high risk cases such as recurrent unprovoked VTE
Hepatocellular & Pancreatic CarcinomasRHMBONCO
The document discusses hepatocellular carcinoma (HCC) and pancreatic cancer, including their epidemiology, risk factors, screening, diagnosis, staging, and management. For HCC, risk factors include hepatitis and other liver diseases, while targeted therapies such as sorafenib have shown efficacy. Surgical resection can cure early HCC but recurrence is common. For pancreatic cancer, risk increases with age and genetic factors, while surgery offers the only chance for cure if the cancer is resectable.
This document discusses hepatocellular carcinoma (HCC). It notes that HCC is one of the most common cancers worldwide and is often associated with cirrhosis from hepatitis B, hepatitis C, or other liver diseases. Screening high-risk patients is important for early detection when treatment may be curative. Treatment options include surgical resection or liver transplantation for early stage disease, and ablation, chemoembolization, or targeted molecular therapies for later stages. However, most patients are not candidates for curative therapies at diagnosis due to late stage, highlighting the importance of screening to detect HCC early.
This document provides an overview of hepatocellular carcinoma (HCC). It discusses the anatomy, epidemiology, screening, diagnosis, staging and management of HCC. HCC is commonly caused by viral hepatitis and cirrhosis. Diagnosis involves imaging such as ultrasound, CT or MRI showing characteristic arterial enhancement and venous washout. Staging systems include AJCC, Okuda, CLIP and BCLC which incorporate tumor burden, liver function and performance status. Management options include surgical resection, liver transplantation, ablation and arterially directed therapies like TACE.
Hepatocellular carcinoma is a primary malignancy of the liver that is now the third leading cause of cancer deaths worldwide. Chronic hepatitis B or C infection and cirrhosis are major risk factors. Treatment options include surgical resection, liver transplantation, radiofrequency ablation, transarterial chemoembolization, and systemic therapies, with resection and transplantation offering the best outcomes for eligible patients with early-stage disease. However, hepatocellular carcinoma commonly recurs within 2 years despite treatment.
Hepatocellular carcinoma (HCC) is the most common type of liver cancer. It has a high worldwide incidence, especially in areas where hepatitis B is prevalent like Southeast Asia. Major risk factors for HCC include hepatitis B and C infections, cirrhosis of the liver from any cause, and alcohol abuse. The disease progresses as hepatocytes undergo repeated cycles of cell death and regeneration due to chronic inflammation and cirrhosis, accumulating mutations over time that can lead to cancer. Diagnosis involves blood tests, imaging like ultrasound or CT scan, and often a biopsy. Staging systems evaluate tumor characteristics, liver function, and physical status to determine prognosis and treatment options. Treatment may include surgical resection, liver transplantation, ablation
Colon cancer is the second and third most common cancer in males and females. Screening programs have led to a reduction in late-stage diagnoses and mortality. Precise identification of prognostic patient groups allows for more targeted adjuvant therapy, improving disease-free and overall survival. Molecular markers of tumor aggressiveness aid in selecting optimal treatment approaches, increasing response rates, progression-free, and overall survival. A multidisciplinary team approach is essential for managing metastatic colon cancer with the goal of surgical cure in organ-limited disease.
DelveInsight’s ‘Triple Negative Breast Cancer (TNBC) - Market Insight, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of TNBC in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Triple Negative Breast Cancer (TNBC) from 2016 to 2027 segmented by G8 markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
The oncology drug market is growing rapidly but faces increasing competition and challenges. Nearly 2,000 drug candidates are in development, with over 1,000 in Phase 2 or later stages. However, the market is maturing, with treatment options already existing for many major cancer types. This will make it difficult for new drugs to achieve blockbuster sales, instead seeing only incremental growth. Follow-on indications for existing drugs make up over half of late-stage pipeline projects, showing the shift towards expanding approved uses of current therapies. The competitive landscape and higher hurdles for reimbursement threaten the viability of the traditional blockbuster sales model in oncology.
The document summarizes hepatocellular carcinoma (HCC) and examines hepatitis C virus (HCV) as a risk factor. It provides descriptive epidemiology on HCC, identifying it as the 4th most common cancer worldwide. It then analyzes HCV as a major risk factor for HCC. Details are given on the virology, epidemiology, transmission routes, stages of infection, diagnosis and treatment of HCV, as well as its role in leading to HCC. Recommendations for primary prevention include national HBV vaccination programs and screening blood supplies.
Hepatocellular carcinoma—role of interventional radiologist Dr. Muhammad Bin ...Dr. Muhammad Bin Zulfiqar
Hepatocellular carcinoma is a leading cause of cancer death worldwide. Interventional radiologists play an important role in diagnosing and treating hepatocellular carcinoma. They can perform biopsies to determine disease, facilitate surgical treatment through techniques like portal vein embolization to increase eligibility for resection, and provide locoregional therapies for patients who are not surgical candidates like radiofrequency ablation, transarterial chemoembolization, and radioembolization. While offering palliation, these minimally invasive treatments can achieve local tumor control and prolong survival for some patients with hepatocellular carcinoma.
This document discusses hepatocellular carcinoma (HCC), the most common type of primary liver cancer. It notes that HCC typically develops in the setting of chronic liver disease. Worldwide, HCC is the 5th most common cancer and the 2nd leading cause of cancer death, with about 600,000 annual deaths. Risk factors for HCC include liver cirrhosis from various causes like viral hepatitis, as well as aflatoxin exposure. Screening with ultrasound and alpha-fetoprotein (AFP) testing every 6 months is recommended for high-risk patients to improve early detection and prognosis. Treatment options depend on tumor stage and liver function, and may include surgical resection, liver transplantation, ablation, and trans
Risk Stratification in Stage II Colon Cancer PatientsRamzi Amri
Objective: AJCC Stage II colon cancer patients form a group where the choice to either undergo or forego adjuvant chemotherapy is far from evident and often remains controversial. This study analyzes several pathological characteristics in order to assess their predictive value for outcomes in stage II colon cancer.
Design: Retrospective review of a prospectively maintained, IRB-approved data repository.
Setting: Tertiary care center.
Patients: A series of 313 consecutive stage II patients treated surgically for colon cancer at our center (2004-2011) were included.
Main outcome measures: Mortality, disease-specific mortality and metastasis, including multivariable Cox regression adjusted for stage subdivisions (II-A/II-B/II-C) and potential confounders.
Results: Colon cancer-specific mortality was substage-independently increased in patients with baseline carcinoembryonic antigen (CEA) >5ng/L (HR=2.97;P=0.041), large vessel invasion (HR=3.93; P=0.002) and perineural invasion (HR=3.67; P=0.004). Overall mortality adjusted for substage, age and comorbidity was also significantly higher in patients with high-grade disease (HR=2.73; P<0.001)><0.001).>5ng/L (HR=2.37; P=0.046), large vessel invasion (HR=2.80; P=0.002), perineural invasion (HR=2.57; P=0.010), and extramural vascular invasion (EMVI) (HR=2.83; P=0.002). The number of high-risk features (0,1,2-3,4+) was associated with a clearly incremental increase in disease-specific mortality (P=0.008) and recurrence (P<0.001).>5ng/L, large vessel invasion, perineural invasion and EMVI are all independent risk factors for recurrence and disease-specific mortality in Stage II colon cancer patients. The number of factors present form risk strata that should be weighed heavily in decisions regarding adjuvant treatment.
Liver cancer diagnostics and Future trendsThet Su Wynn
Liver cancer is usually diagnosed through a combination of tumor marker tests, imaging scans, and biopsy. Serum markers like AFP, AFP-L3, and PIVKA-II provide early screening but lack specificity. Ultrasound, CT, and MRI scans use contrast agents to detect hypervascular lesions during arterial wash-in and wash-out, but are not definitive. Biopsy confirms the diagnosis by examining tissue samples for liver cell abnormalities, fibrosis, and marker expression through histology and IHC staining. Future areas of research include improved non-invasive diagnostic tools using genetic markers like miRNA profiles and tumor-specific genes.
1) Liver transplantation provides the best chance of cure for hepatocellular carcinoma (HCC) in cirrhotic livers, but is limited by organ availability. The Milan criteria, which select patients with very early HCC, have been expanded to include slightly larger tumors without reducing survival.
2) Patients with HCC can be prioritized for liver transplant by receiving exception MELD scores, but these are only granted if tumors can be downstaged within defined criteria through treatments like ablation. Successful downstaging selects less aggressive tumors and predicts good post-transplant survival.
3) While downstaging expands access to transplant for some patients with larger tumors, eligibility criteria remain unclear as very advanced disease carries a
This document provides an overview of the management of hepatocellular carcinoma (HCC). It discusses the epidemiology, risk factors, diagnosis and staging, as well as treatment options for HCC. The major risk factors for HCC include hepatitis B virus, hepatitis C virus, and alcohol. Treatment depends on the stage and includes options such as liver transplantation, resection, ablation, transarterial chemoembolization, and the systemic therapy sorafenib. Prevention through vaccination and treating underlying liver diseases can help reduce cases of HCC.
This document provides the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Neuroendocrine and Adrenal Tumors. It was last updated in January 2019 and is authored by an expert panel assembled by NCCN. The guidelines provide evidence-based recommendations for diagnosis, staging, treatment and surveillance of neuroendocrine tumors and adrenal tumors. The key updates from the previous version include expanding the name to include adrenal tumors, preferring gallium-68 dotatate PET/CT for somatostatin receptor imaging, and adding peptide receptor radionuclide therapy with lutetium-177 as a treatment option.
Venous Thromboembolism in the Cancer Patientlarriva
Cancer patients are at an increased risk of venous thromboembolism. There have been several guidelines published on the topic from the American College of Chest Physicians (ACCP), the American Society of Clinical Oncology (ASCO), and the National Comprehensive Cancer Network (NCCN). Although they agree on some issues regarding prophylaxis and treatment there are several areas that vary. This presentation covers the varying recommendations and the areas of consensus (yellow boxes) among the guidelines while using a patient case to guide their interpretation.
Venous thromboembolism (VTE) can be the first sign of an underlying occult or undiagnosed cancer. The risk of occult cancer is higher in patients with unprovoked VTE compared to those with VTE from a provoking factor. Limited screening is recommended for patients over age 40 presenting with unprovoked VTE, including a complete blood count, basic metabolic panel, chest imaging, and consideration of tumor markers based on risk factors. More extensive screening with CT scans is not supported by evidence of improved outcomes and poses risks of unnecessary anticoagulation withdrawal or additional testing. Ongoing surveillance beyond initial screening may be warranted in certain high risk cases such as recurrent unprovoked VTE
Hepatocellular & Pancreatic CarcinomasRHMBONCO
The document discusses hepatocellular carcinoma (HCC) and pancreatic cancer, including their epidemiology, risk factors, screening, diagnosis, staging, and management. For HCC, risk factors include hepatitis and other liver diseases, while targeted therapies such as sorafenib have shown efficacy. Surgical resection can cure early HCC but recurrence is common. For pancreatic cancer, risk increases with age and genetic factors, while surgery offers the only chance for cure if the cancer is resectable.
This document discusses hepatocellular carcinoma (HCC). It notes that HCC is one of the most common cancers worldwide and is often associated with cirrhosis from hepatitis B, hepatitis C, or other liver diseases. Screening high-risk patients is important for early detection when treatment may be curative. Treatment options include surgical resection or liver transplantation for early stage disease, and ablation, chemoembolization, or targeted molecular therapies for later stages. However, most patients are not candidates for curative therapies at diagnosis due to late stage, highlighting the importance of screening to detect HCC early.
This document provides an overview of hepatocellular carcinoma (HCC). It discusses the anatomy, epidemiology, screening, diagnosis, staging and management of HCC. HCC is commonly caused by viral hepatitis and cirrhosis. Diagnosis involves imaging such as ultrasound, CT or MRI showing characteristic arterial enhancement and venous washout. Staging systems include AJCC, Okuda, CLIP and BCLC which incorporate tumor burden, liver function and performance status. Management options include surgical resection, liver transplantation, ablation and arterially directed therapies like TACE.
Hepatocellular carcinoma is a primary malignancy of the liver that is now the third leading cause of cancer deaths worldwide. Chronic hepatitis B or C infection and cirrhosis are major risk factors. Treatment options include surgical resection, liver transplantation, radiofrequency ablation, transarterial chemoembolization, and systemic therapies, with resection and transplantation offering the best outcomes for eligible patients with early-stage disease. However, hepatocellular carcinoma commonly recurs within 2 years despite treatment.
Hepatocellular carcinoma (HCC) is the most common type of liver cancer. It has a high worldwide incidence, especially in areas where hepatitis B is prevalent like Southeast Asia. Major risk factors for HCC include hepatitis B and C infections, cirrhosis of the liver from any cause, and alcohol abuse. The disease progresses as hepatocytes undergo repeated cycles of cell death and regeneration due to chronic inflammation and cirrhosis, accumulating mutations over time that can lead to cancer. Diagnosis involves blood tests, imaging like ultrasound or CT scan, and often a biopsy. Staging systems evaluate tumor characteristics, liver function, and physical status to determine prognosis and treatment options. Treatment may include surgical resection, liver transplantation, ablation
Colon cancer is the second and third most common cancer in males and females. Screening programs have led to a reduction in late-stage diagnoses and mortality. Precise identification of prognostic patient groups allows for more targeted adjuvant therapy, improving disease-free and overall survival. Molecular markers of tumor aggressiveness aid in selecting optimal treatment approaches, increasing response rates, progression-free, and overall survival. A multidisciplinary team approach is essential for managing metastatic colon cancer with the goal of surgical cure in organ-limited disease.
DelveInsight’s ‘Triple Negative Breast Cancer (TNBC) - Market Insight, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of TNBC in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Triple Negative Breast Cancer (TNBC) from 2016 to 2027 segmented by G8 markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
The oncology drug market is growing rapidly but faces increasing competition and challenges. Nearly 2,000 drug candidates are in development, with over 1,000 in Phase 2 or later stages. However, the market is maturing, with treatment options already existing for many major cancer types. This will make it difficult for new drugs to achieve blockbuster sales, instead seeing only incremental growth. Follow-on indications for existing drugs make up over half of late-stage pipeline projects, showing the shift towards expanding approved uses of current therapies. The competitive landscape and higher hurdles for reimbursement threaten the viability of the traditional blockbuster sales model in oncology.
Anal Cancer Market 2023: Epidemiology, Industry Trends, Size, Share And Forec...frankmorgan27
The Anal Cancer Market report thoroughly examines the market size, latest trends, and growth forecast. The report includes an overview of the disease and market scenario, as well as market trends, growth prospects, investment opportunities, and industry prospects. Additionally, it provides competitor analysis, regional analysis, and recent advancements in the Anal Cancer Market.
HIV Drugs Market Competitive Research And Precise Outlook 2023 To 2030subishsam
The research firm Contrive Datum Insights has just recently added to its database a report with the heading global HIV Drugs Market .Both primary and secondary research methodologies have been utilised in order to conduct an analysis of the worldwide HIV Drugs Market . In order to provide a comprehensive comprehension of the topic at hand, it has been summed up using appropriate and accurate market insights. According to Contrive Datum Insights, this worldwide comprehensive report is broken up into several categories in order to present the data in a way that is understandable, succinct,
Cancer Tumor Profiling Market Growth, Demand and Challenges of the Key Indust...IMARC Group
The global cancer tumor profiling market reached a value of US$ 9.38 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 18.22 Billion by 2027 exhibiting a growth rate (CAGR) of 11.20% during 2022-2027.
More Info:- https://www.imarcgroup.com/cancer-tumor-profiling-market
Global antibody drug conjugate market & pipeline insight2020KuicK Research
" Global Antibody Drug Conjugate Market & Pipeline Insight 2020" Report Highlight:
Global Antibody Drug Conjugates Market Overview
Mechanism of Antibody Drug Conjugates
Global Antibody Drug Conjugates Clinical Pipeline by Company, Indication & Phase
Global Antibody Drug Conjugates Clinical Pipeline: 148 ADC
Marketed Antibody Drug Conjugates Clinical Insight: 8 ADC
Antibody Drug Conjugates Patent Analysis
Global Antibody Drug Conjugates Market Future Prospects
Download Global antibody drug conjugate market & pipeline insight2020KuicK Research
\" Global Antibody Drug Conjugate Market & Pipeline Insight 2020\" Report Highlight:
Global Antibody Drug Conjugates Market Overview
Mechanism of Antibody Drug Conjugates
Global Antibody Drug Conjugates Clinical Pipeline by Company, Indication & Phase
Global Antibody Drug Conjugates Clinical Pipeline: 148 ADC
Marketed Antibody Drug Conjugates Clinical Insight: 8 ADC
Antibody Drug Conjugates Patent Analysis
Global Antibody Drug Conjugates Market Future Prospects
Liquid Biopsy Market PPT 2023: Size, Growth, Demand and Forecast till 2028IMARC Group
The global liquid biopsy market size reached US$ 1.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.3 Billion by 2028, exhibiting a growth rate (CAGR) of 15.3% during 2023-2028.
More Info:- https://www.imarcgroup.com/liquid-biopsy-market
A presentation of Genentech strategic growth options vis-a-vis the current economic and structural challenges the biotech industry is facing.
Team project, December 2008.
The global immuno-oncology market is expected to exceed USD 38.89 billion by 2025, growing at a CAGR of 21.8%. Immuno-oncology or cancer immunotherapy enhances the body's natural defenses to stop cancer growth by using constituents made by the body or in a lab to improve immune system function. Key treatment approaches include monoclonal antibodies, therapeutic vaccines, checkpoint inhibitors, and cytokines while novel targets under investigation include IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, and more. The market is segmented by tumor type and region, with North America currently being the largest market due to high cancer treatment spending and innovation in immuno-oncology treatments.
Invitae's 36th Annual J.P. Morgan Healthcare Conference Presentationinvitaeir
This document discusses Invitae Corporation's growth and strategy in genetic testing. It notes that Invitae set new records in 2017 with over 134,000 samples accessioned and revenue of around $59 million. It aims to simplify genetic testing, make information more accessible, and transform the field from testing to information management. Invitae plans to continue growing in 2018, anticipating at least 250,000 samples and doubling its 2017 revenue to $120 million through expanding its product breadth, partnerships, and selective acquisitions.
Colorectal Cancer Market 2023: Epidemiology, Industry Trends, Size, Share And...frankmorgan27
The increasing occurrences of polyps and inflammatory bowel conditions like ulcerative colitis or Crohn’s disease are primarily propelling the colorectal cancer market.
Will reimbursement prove to be the biggest barrier as three gene therapies gain regulatory approval?
Datamonitor Healthcare has carried out a comprehensive analysis of gene therapy products in commercial development worldwide based on information derived from Pharmaprojects. The results have been analyzed to reveal trends in gene therapy technologies and approaches to the treatment of different diseases.
The number of gene therapy products in preclinical to Phase III and beyond stages of development doubled between 2012 and 2015. Additionally, three gene therapy products – Glybera (uniQure), Imlygic (Amgen), and Strimvelis (GlaxoSmithKline) – have now received regulatory approval in Europe. While these approvals give some validation to gene therapy as a therapeutic strategy, doubts remain around their return on investment. The high upfront costs and residual uncertainty around the long-term benefits of gene therapy products are proving to be hurdles to wider access and reimbursement, but seem to have had a minimal impact on companies’ appetite to dive into this arena, with cancer and monogenic diseases proving to be the most popular indications for the development of gene therapy products.
For more information on this report visit https://pharmastore.informa.com/product/trends-gene-therapy/
Cancer Biomarkers Market PPT 2023: Size, Growth, Demand and Forecast till 2028IMARC Group
The global cancer biomarkers market size reached US$ 24.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 53.7 Billion by 2028, exhibiting a growth rate (CAGR) of 12.95% during 2023-2028.
More Info:- https://www.imarcgroup.com/cancer-biomarkers-market
Hepatitis C Market 2023: Epidemiology, Industry Trends, Size, Share And Forec...frankmorgan27
The growing utilization of injection drugs, which involves the use of needle and syringe sharing that can lead to the risk of virus transmission, is primarily driving the hepatitis C market.
Parkville strategic project final-convertedMohamed Ahmed
Parkville Pharmaceuticals is an Egyptian pharmaceutical company established in 2006 with headquarters in Alexandria and Cairo. It has grown from a small local company to a multinational company with over 175 employees and a diverse product range including pharmaceuticals, cosmeceuticals, dietary supplements, and medical devices. Parkville's vision is to be a key player in healthcare in the Middle East and Africa by 2025 and expand globally thereafter. Its mission is to have a strong presence in the Egyptian market and gain momentum in other fast-growing markets through innovative, high-quality, affordable products. A PESTEL analysis identifies opportunities and threats in the company's external environment.
The document analyzes Varian Medical Systems, a manufacturer of cancer treatment devices. It recommends exiting the position due to several factors, including domestic headwinds in the hospital industry, the re-emergence of an excise tax that will reduce cash flow, and emerging competitors in proton therapy eroding Varian's market share as costs are reduced. It also notes Varian has failed to deliver on past thesis points and upside catalysts.
Cancer Biomarkers Market by Product Type, Distribution Channel, End User 2024...IMARC Group
The global cancer biomarkers market size reached US$ 27.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 77.0 Billion by 2032, exhibiting a growth rate (CAGR) of 11.7% during 2024-2032.
More Info:- https://www.imarcgroup.com/cancer-biomarkers-market
The most thrilling international pharma events, from conferences to meetings & workshops, this is the list not to be missed for pharma professionals.
Check out our list of Top 10 Pharmaceutical conferences:
1. International Conference on Cell and Gene Therapy
2. BIO-Europe Spring 2021
3. DUPHAT- 2021 : https://duphat.ae/
4. CPHI India 2021
5. DIA Europe 2021
6. BIO Asia International Conference 2021
7. BIO International Convention
8. CAR TCR EUROPE 2021
9. Pharma Forum 2021
10. 4th Annual Bioprocessing Summit Europe
DelveInsight’s ‘Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast-2030’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Soft Tissue Sarcoma (STS) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
https://www.delveinsight.com/report-store/soft-tissue-sarcoma-market
The Soft Tissue Sarcoma market report provides analysis regarding current treatment practices, emerging drugs like AL3818, Fibromun, AL3818, Ripretinib, market share of the individual therapies, historical, current and forecasted Soft Tissue Sarcoma market Size from 2017 to 2030 segmented by seven major markets.
Non-Small Cell Lung Cancer Pipeline Insight | Non-Small Cell Lung Cancer Pipe...Dr. B.K. Agrawal
NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.
Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7...Dr. B.K. Agrawal
DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio.
Key Highlights from report are:
As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017. These cases are expected to grow with a significant CAGR in the study period 2017–2030.
There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.
The market size of NSCLC in the 7MM is expected to increase during study period. According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.
This document provides a list of the top 10 international cell therapy conferences in 2020. The conferences cover topics related to cell and gene therapy research and applications, including CAR-T cell therapies, regenerative medicine, tissue engineering, bioprocessing, manufacturing, and clinical trials. The conferences will take place in various locations around the world, including Europe, Asia, and North America, between February and October 2020.
Cholangiocarcinoma is a rare and heterogeneous malignant neoplasm with epithelial cell origin of biliary duct and histologic and biochemical features of cholangiocyte differentiation. The malignant tumor may arise from any portion of the bile duct i.e., from terminal ductules to the ampulla of Vater, and at the peribiliary glands.
Charcot Marie tooth disease is one of the hereditary motor and sensory neuropathies, a group of varied inherited disorders of the peripheral nervous system characterized by progressive loss of muscle tissue and touch sensation across various parts of the body.
Acute Respiratory Distress Syndrome (ARDS) is a life-threatening severe orphan disease in which the air sacs present in alveoli are filled with fluid and lower the amount of oxygen in the blood. Thus, enough oxygen is not supplied to the body. Inflammation may occur throughout the lungs.
Acute Bacterial Skin and Skin-Structure Infection-ABSSSIDr. B.K. Agrawal
DelveInsight’s ABSSSI market report gives a thorough understanding of Acute Bacterial Skin and Skin-Structure Infection. It provides ABSSSI treatment algorithms and ABSSSI treatment guidelines in the US, Europe, and Japan. The ABSSSI market outlook of the report helps to build the detailed comprehension of the historical, current and forecasted trend of the ABSSSI market by analysing the impact of current therapies on the market, unmet needs, ABSSSI market drivers and ABSSSI market barriers and demand of better technology.
For more information on ABSSSI market, click here: <a href="https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infection-absssi-market-insights-epidemiology-and-market-forecast">ABSSSI Market</a>
This document provides an overview and market insights into house dust mite allergy (HDMA). It discusses that HDMA is an allergic reaction to dust mites commonly found in house dust. The two main species that cause allergy reactions are Dermatophagoides pteronyssinus and Dermatophagoides farinae. Signs of dust mite allergy include sneezing, runny nose and other hay fever-like symptoms. Dust mites thrive in warm, humid environments. The document reviews prevalence, diagnosed cases, treatment guidelines, marketed products and upcoming therapies. It provides market size data by region and forecasts growth during 2018-2027 due to new product launches. Major players in the HDMA
Allergic rhinitis, also known as hay fever, is a type
of inflammation in the nose which occurs when
the immune system overreacts to allergens in the
air. Signs and symptoms include a runny or stuffy
nose, sneezing, red, itchy, and watery eyes, and
swelling around the eyes.
Healthy Eating Habits:
Understanding Nutrition Labels: Teaches how to read and interpret food labels, focusing on serving sizes, calorie intake, and nutrients to limit or include.
Tips for Healthy Eating: Offers practical advice such as incorporating a variety of foods, practicing moderation, staying hydrated, and eating mindfully.
Benefits of Regular Exercise:
Physical Benefits: Discusses how exercise aids in weight management, muscle and bone health, cardiovascular health, and flexibility.
Mental Benefits: Explains the psychological advantages, including stress reduction, improved mood, and better sleep.
Tips for Staying Active:
Encourages consistency, variety in exercises, setting realistic goals, and finding enjoyable activities to maintain motivation.
Maintaining a Balanced Lifestyle:
Integrating Nutrition and Exercise: Suggests meal planning and incorporating physical activity into daily routines.
Monitoring Progress: Recommends tracking food intake and exercise, regular health check-ups, and provides tips for achieving balance, such as getting sufficient sleep, managing stress, and staying socially active.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...rightmanforbloodline
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
Chandrima Spa Ajman is one of the leading Massage Center in Ajman, which is open 24 hours exclusively for men. Being one of the most affordable Spa in Ajman, we offer Body to Body massage, Kerala Massage, Malayali Massage, Indian Massage, Pakistani Massage Russian massage, Thai massage, Swedish massage, Hot Stone Massage, Deep Tissue Massage, and many more. Indulge in the ultimate massage experience and book your appointment today. We are confident that you will leave our Massage spa feeling refreshed, rejuvenated, and ready to take on the world.
Visit : https://massagespaajman.com/
Call : 052 987 1315
At Malayali Kerala Spa Ajman, Full Service includes individualized care for every client. We specifically design each massage session for the individual needs of the client. Our therapists are always willing to adjust the treatments based on the client's instruction and feedback. This guarantees that every client receives the treatment they expect.
By offering a variety of massage services, our Ajman Spa Massage Center can tackle physical, mental, and emotional illnesses. In addition, efficient identification of specific health conditions and designing treatment plans accordingly can significantly enhance the quality of massaging.
At Malayali Kerala Spa Ajman, we firmly believe that everyone should have the option to experience top-quality massage services regularly. To achieve that goal we offer cheap massage services in Ajman.
If you are interested in experiencing transformative massage treatment at Malayali Kerala Spa Ajman, you can use our Ajman Massage Center WhatsApp Number to schedule your next massage session.
Contact @ +971 529818279
Visit @ https://malayalikeralaspaajman.com/
We are one of the top Massage Spa Ajman Our highly skilled, experienced, and certified massage therapists from different corners of the world are committed to serving you with a soothing and relaxing experience. Luxuriate yourself at our spas in Sharjah and Ajman, which are indeed enriched with an ambiance of relaxation and tranquility. We could confidently claim that we are one of the most affordable Spa Ajman and Sharjah as well, where you can book the massage session of your choice for just 99 AED at any time as we are open 24 hours a day, 7 days a week.
Visit : https://massagespaajman.com/
Call : 052 987 1315
At Apollo Hospital, Lucknow, U.P., we provide specialized care for children experiencing dehydration and other symptoms. We also offer NICU & PICU Ambulance Facility Services. Consult our expert today for the best pediatric emergency care.
For More Details:
Map: https://cutt.ly/BwCeflYo
Name: Apollo Hospital
Address: Singar Nagar, LDA Colony, Lucknow, Uttar Pradesh 226012
Phone: 08429021957
Opening Hours: 24X7
The facial nerve, also known as cranial nerve VII, is one of the 12 cranial nerves originating from the brain. It's a mixed nerve, meaning it contains both sensory and motor fibres, and it plays a crucial role in controlling various facial muscles, as well as conveying sensory information from the taste buds on the anterior two-thirds of the tongue.
MYASTHENIA GRAVIS POWER POINT PRESENTATIONblessyjannu21
Myasthenia gravis is a neurological disease. It affects the grave muscles in our body. Myasthenia gravis affects how the nerves communicate with the muscles. Drooping eyelids and/or double vision are often the first noticeable sign. It is involving the muscles controlling the eyes movement, facial expression, chewing and swallowing. It also effects the muscles neck and lip movement and respiration.
It is a neuromuscular disease characterized by abnormal weakness of voluntary muscles that improved with rest and the administration of anti-cholinesterase drugs.
The person may find difficult to stand, lift objects and speak or swallow. Medications and surgery can help the patient to relieve the symptoms of this lifelong illness.
Michigan HealthTech Market Map 2024. Includes 7 categories: Policy Makers, Academic Innovation Centers, Digital Health Providers, Healthcare Providers, Payers / Insurance, Device Companies, Life Science Companies, Innovation Accelerators. Developed by the Michigan-Israel Business Accelerator
International Cancer Survivors Day is celebrated during June, placing the spotlight not only on cancer survivors, but also their caregivers.
CANSA has compiled a list of tips and guidelines of support:
https://cansa.org.za/who-cares-for-cancer-patients-caregivers/